TRU-016 regulatory update

Emergent said the European Commission granted Orphan Drug designation for TRU-016 to treat chronic lymphocytic leukemia (CLL). The humanized small modular immunopharmaceutical (SMIP) that targets the CD37 antigen has Orphan Drug designation in the U.S. Emergent is evaluating the product in the Phase II portion of a Phase Ib/II trial to treat CLL. Data are expected next half. ...